Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
14.13
-0.64 (-4.33%)
At close: Jan 17, 2025, 4:00 PM
14.05
-0.08 (-0.57%)
After-hours: Jan 17, 2025, 4:33 PM EST
Dyne Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
141
Market Cap
1.44B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
DYN News
- 10 days ago - Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday? - Benzinga
- 10 days ago - Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 - GlobeNewsWire
- 11 days ago - Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 12 days ago - Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET - GlobeNewsWire
- 2 months ago - Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases - Seeking Alpha
- 2 months ago - Dyne Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - The Schall Law Firm Encourages Investor Participation In An Inquiry Into Dyne Therapeutics, Inc. For Possible Securities Law Violations - Accesswire
- 2 months ago - Dyne Therapeutics Inc Is Being Investigated For Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm - Accesswire